<DOC>
	<DOCNO>NCT02575365</DOCNO>
	<brief_summary>This 24-month , open-label , multicenter study single treatment arm design . Primary objective study : -To investigate effect Fingolimod cognitive performance highly active relapse remit multiple sclerosis patient Secondary objective study : - To investigate correlation effect fingolimod cognitive performance MRI data . - To evaluate effect fingolimod biomarkers ( 24 hydroxy cholesterol , osteopontin matrix metalloproteinases ) relate neurodegeneration - To investigate effect fingolimod brain gray matter atrophy thalamic atrophy . Polulation We recruit minimum 80 relapse remit MS ( RRMS ) patient accord McDonald criterion .</brief_summary>
	<brief_title>Effect Fingolimod Neurodegeneration</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Nerve Degeneration</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>1 . Diagnosed RRMS described 2010 McDonald criterion ( 36 ) 2 . Provided write informed consent prior intervention 3 . Unresponsive treatment beta interferon glatiramer acetate minimum one year adequate dose high disease activity ( Unresponsive patient : patient change relapse , increased relapse , severer relapse oneyear treatment least one relapse past one year previous treatment one multiple contrast enhance lesion cranial MRI increase T2 lesion successive MRIs ) 4 . EDSS score 5.5 screen 1 . Patients primary secondary progressive progressive relapse MS. 2 . Patients known contraindication fingolimod treatment . 3 . Other coexistent autoimmune disease include Hashimoto thyroiditis , systemic lupus erythematosus , rheumatoid anthiritis , psoriasis etc . 4 . Patients follow cardiovascular condition : Resting heart rate &lt; 45 bpm/min Cardiac failure time first study visit ( Class III per NYHA classification ) significant heart disease judge physician Myocardial infarction last 6 month History Mobitz Type II grade 2 AV block Past current grade 3 AV block Confirmed history sick sinus syndrome sinoatrial heart block arrhythmia require current treatment Class Ia drug ( ajmaline , disopyramid , procainamide , quinidine ) hypertension uncontrolled medication 5 . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . 6 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , detect urinalysis confirm positive hCG laboratory test . 7 . Negative varicellazoster virus IgG antibodies screen . Patients negative result varicellazoster virus IgG antibody include study vaccination varicellazoster virus . 8 . Active systemic bacterial , viral fungal infection , diagnosis AIDS , Hepatitis B , Hepatitis C infection define positive HIV antibody , Hepatitis B surface antigen Hepatitis C antibody test , respectively 9 . History previous fingolimod therapy 10 . Patient receive treatment : 1 . Corticosteroids adrenocorticotropic hormone ( ACTH ) last 1 month 2 . Immunosuppressive medication azathioprine methotrexate etc . 3 . Immunoglobulin treatment last 3 month 4 . Cladribine , cyclophosphamide , mitoxantrone , natalizumab time</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>RRMS ,</keyword>
	<keyword>Cognition ,</keyword>
	<keyword>brain ,</keyword>
	<keyword>Fingolimod ,</keyword>
	<keyword>Multiple Sclerosis ,</keyword>
	<keyword>neurodegeneration ,</keyword>
	<keyword>Brain atrophy ,</keyword>
	<keyword>gray matter atrophy ,</keyword>
	<keyword>thalamic atrophy ,</keyword>
	<keyword>biomarkers ,</keyword>
	<keyword>BICAMS Battery ,</keyword>
</DOC>